LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

81.85 0.94

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

80.76

Max

82.98

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-254M

-103M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+20.62% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-25

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.4B

13B

Ankstesnė atidarymo kaina

80.91

Ankstesnė uždarymo kaina

81.85

Naujienos nuotaikos

By Acuity

58%

42%

302 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-18 22:31; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026-02-18 22:18; UTC

Uždarbis

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026-02-18 22:11; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026-02-18 21:52; UTC

Uždarbis

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026-02-18 23:56; UTC

Rinkos pokalbiai

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-18 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026-02-18 23:34; UTC

Rinkos pokalbiai
Uždarbis

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026-02-18 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026-02-18 23:32; UTC

Rinkos pokalbiai

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026-02-18 22:45; UTC

Uždarbis

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026-02-18 22:44; UTC

Rinkos pokalbiai

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q EPS $1.18 >NTR.T

2026-02-18 22:37; UTC

Uždarbis

Nutrien 4Q Sales $5.34B >NTR.T

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q EPS $1.07 >PAAS

2026-02-18 22:35; UTC

Uždarbis

Pan American Silver 4Q Rev $1.18B >PAAS

2026-02-18 22:30; UTC

Uždarbis

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026-02-18 22:29; UTC

Uždarbis

Kinross Gold 4Q EPS 75c >K.T

2026-02-18 22:22; UTC

Uždarbis

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026-02-18 22:22; UTC

Rinkos pokalbiai

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026-02-18 22:16; UTC

Uždarbis

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026-02-18 22:05; UTC

Uždarbis

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026-02-18 22:03; UTC

Uždarbis

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q Sales $929M >KALU

2026-02-18 22:02; UTC

Uždarbis

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Adj EPS 67c >KGC

2026-02-18 22:00; UTC

Uždarbis

Kinross Gold 4Q Sales $2.02B >KGC

2026-02-18 21:56; UTC

Uždarbis

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026-02-18 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

20.62% į viršų

12 mėnesių prognozė

Vidutinis 97.22 USD  20.62%

Aukščiausias 110 USD

Žemiausias 87 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

302 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat